Pharmaceuticals News & Press Release Distribution

Nona Biosciences Expands Antibody Discovery Collaboration with BeiGene

CAMBRIDGE, Mass., Sept. 14, 2023 /PRNewswire/ -- Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited, committed to cutting edge antibody technology innovation and provider of integrated antibody discovery and development solutions from "Idea to IND" (I to I™), announced an agreeme...

2023-09-14 16:00 1253

Innovative Collaboration: Buzzreach and Oncoshot Spearhead Clinical Trial Advancements in Japan

SINGAPORE, Sept. 14, 2023 /PRNewswire/ -- Buzzreach and Oncoshot, two prominent entities in the clinical trials domain, have announced an impactful collaboration to accelerate clinical trials inJapan. The former specialises in clinical trial site recruitment and retention and project managemen...

2023-09-14 10:00 1948

Innovative Collaboration: Buzzreach and Oncoshot Spearhead Clinical Trial Advancements in Japan

Exelixis and Insilico Medicine Enter into Exclusive Global License Agreement for ISM3091, a Potentially Best-in-Class USP1 Inhibitor

— ISM3091 is a highly selective, orally bioavailable small molecule inhibitor of USP1 identified through Insilico Medicine's artificial intelligence (AI) platform, with potent activity in BRCA-mutated tumor models — — In May 2023, the U.S. Food and Drug Administration (FDA) cleared Insilico's I...

2023-09-13 20:29 1591

J INTS BIO, WCLC 2023 - Presentation of Phase 1/2 study of 'JIN-A02', a Novel Oral 4th Generation EGFR TKI

SEOUL, South Korea, Sept. 13, 2023 /PRNewswire/ -- J INTS BIO announced that Phase 1/2 study of its novel, orally administered 4th generation EGFR-TKI 'JIN-A02' was presented at the 2023 IASLC World Conference on Lung Cancer held inSingapore from 9th to 12th September, during the official session...

2023-09-13 15:58 1428

J INTS BIO, WCLC 2023 - Presentation of Phase 1/2 study of 'JIN-A02', a Novel Oral 4th Generation EGFR TKI

Zuberitamab (Anruixi®), the first domestically developed anti-CD20 antibody as a Class I innovative drug from BioRay Pharmaceutical, has been approved for marketing in China

SHANGHAI, Sept. 13, 2023 /PRNewswire/ -- Recently, BioRay Pharmaceutical Co., Ltd. (hereinafter referred to as "Bioray") announced that its independently developed Class I innovative therapeutic biological product, Zuberitamab Injection (trade name: Anruixi®), indicated for the treatment of CD20...

2023-09-13 14:24 1239

Caliway Announces CBL-514 Phase 2 Study Topline Results for Dercum's Disease, Showing 64.5% of Lipomas with Complete Clearance or Dimensions Reduction of Over 50% and Reduced Pain by 4.7

- CBL-0201DD Phase 2 study met the primary and all secondary endpoints. - 64.5% of painful lipomas showed complete clearance or dimensions reduction of more than 50% after CBL-514 treatments. - 54.8% of painful lipomas showed complete clearance or dimension reduction of more th...

2023-09-13 13:42 1158

Menarini Asia-Pacific Enters into an Exclusive Licensing Agreement with Astellas to Commercialize Smyraf® in Taiwan and select South-East Asian markets

SINGAPORE, Sept. 13, 2023 /PRNewswire/ -- Menarini Asia-Pacific has entered into a long-term exclusive licensing partnership with Astellas Pharma Inc. (Astellas) for the development, manufacturing and commercialization of the orally administered Janus kinase (JAK) inhibitor Smyraf® 50 mg and 100 ...

2023-09-13 10:30 2154

GemPharmatech's Board Appoints Brandy Wilkinson, Ph.D. as its New Chief Executive Officer of GemPharmatech LLC.

SAN DIEGO, Sept. 12, 2023 /PRNewswire/ -- GemPharmatech LLC., a leading contract research organization, announced today that its Board of Directors has appointed Dr.Brandy Wilkinson as the Chief Executive Officer of its subsidiary inthe United States, effective September 12, 2023.

2023-09-13 00:00 1300

GemPharmatech's Board Appoints Brandy Wilkinson, Ph.D. as its New Chief Executive Officer of GemPharmatech LLC.

Pierre Fabre Laboratories Acquires Vertical Bio and its Innovative Targeted Therapy Candidate for Patients Suffering From Non-Small Cell Lung Cancer With MET Alteration

CASTRES, France and BASEL, Switzerland, Sept. 12, 2023 /PRNewswire/ -- Pierre Fabre Laboratories , the French pharmaceutical and dermo-cosmetic company, announced the acquisition of Vertical Bio AG, a developer of novel cancer therapies. This first acquisition of...

2023-09-12 20:00 1255

Henlius Expands Collaboration with KGbio to Develop, Commercialize and Supply Henlius' novel anti-PD-1 mAb HANSIZHUANG in MENA

* HANSIZHUANG's coverage footprint includes 22 emerging market countries acrossSoutheast Asia and MENA – * KGbio to develop and commercialise HANSIZHUANG in 12 MENA countries; Henlius to receiveUS$7 million upfront payment plus royalties and up to US$8 million in regulatory milestone payments...

2023-09-12 19:24 1229

IPMG Drives Health Transformation and Strengthens Indonesia's Economy Through Efforts to Accelerate Access to Innovative Medicines and Vaccines, also Partnerships

JAKARTA, Indonesia, Sept. 11, 2023 /PRNewswire/ -- The research and development-based multinational pharmaceutical industry association, the International Pharmaceutical Manufacturers Group (IPMG) is always committed to supporting and encouraging advocacy and transformation of Government policie...

2023-09-11 18:52 1804

IPMG Drives Health Transformation and Strengthens Indonesia's Economy Through Efforts to Accelerate Access to Innovative Medicines and Vaccines, also Partnerships

Norgine Strengthens Senior Leadership with the Appointment of Saulo Martiniano as Chief Operating Officer

AMSTERDAM, Sept. 11, 2023 /PRNewswire/ -- Norgine, a leading European specialist pharmaceutical company dedicated to improving the lives of patients, is pleased to announce the appointment ofSaulo Martiniano as its new Chief Operating Officer (COO). Saulo joins Norgine with a wealth of experience...

2023-09-11 15:00 1040

Norgine Strengthens Senior Leadership with the Appointment of Saulo Martiniano as Chief Operating Officer

AMSTERDAM, Sept. 11, 2023 /PRNewswire/ -- Norgine, a leading European specialist pharmaceutical company dedicated to improving the lives of patients, is pleased to announce the appointment ofSaulo Martiniano as its new Chief Operating Officer (COO). Saulo joins Norgine with a wealth of experience...

2023-09-11 15:00 1106

Biosyngen received FDA approval for Phase I/II Clinical Trials for BRL03, targeting Lung Cancer, Gastric Cancer and other advanced Solid Tumors

SINGAPORE, Sept. 11, 2023 /PRNewswire/ -- On September 9th, 2023, Biosyngen Pte Ltd (hereafter as "Biosyngen") announced that the U.S. FDA has cleared the Investigational New Drug (IND) application for Phase I/II clinical trial ofBRL03 for the treatment of lung cancer, gastric cancer and other ad...

2023-09-11 14:53 1126

Biosyngen received FDA approval for Phase I/II Clinical Trials for BRL03, targeting Lung Cancer, Gastric Cancer and other advanced Solid Tumors

Nobel Trust Family Joins BIOHK2023 - Unveiling Key Announcement

HONG KONG, Sept. 8, 2023 /PRNewswire/ -- BIOHK2023 garnered widespread acclaim featuring an exceptional lineup of speakers, including aNobel Laureate, world-renowned scientists who have won distinguished awards, and accomplished biotech C-level venture capitalists taking the stage on 13th to 16th...

2023-09-08 16:30 2167

Nobel Trust Family Joins BIOHK2023 - Unveiling Key Announcement

Mabwell and WuXi XDC Sign Long-Term ADC Strategic Collaboration to Accelerate Global Layout of Innovative Biologics

SHANGHAI, Sept. 8, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, and WuXi XDC, a leading global CRDMO, joint announced that they have signed a LOI for long-term strategic collaboration on Mabwell's multiple ADC projects. Mabwell has...

2023-09-08 15:30 1345

SIFI TO PRESENT NEW SCIENTIFIC DATA DURING THE 41ST CONGRESS OF THE EUROPEAN SOCIETY OF CATARACT AND REFRACTIVE SURGEONS

CATANIA, Italy, Sept. 8, 2023 /PRNewswire/ -- SIFI, a leading international ophthalmic company, is pleased to announce the presentation of new scientific data on its products during the upcomingCongress of The European Society of Cataract and Refractive Surgeons (ESCRS) which will take place from...

2023-09-08 14:00 1656

Adagene to Present at Investor and Scientific Conferences in September

- Adagene's CEO and President of R&D, Dr. Peter Luo, participating in SITC webinar onSeptember 22 focused on essential role of Treg depletion for anti-CTLA-4 therapies - SAN DIEGO and SUZHOU, China, Sept. 8, 2023 /PRNewswire/ -- Adagene Inc. ("Adagene") (Nasdaq: ADAG), a platform-driven, clinic...

2023-09-08 10:45 1685

World Orphan Drug Alliance Welcomes Specialised Therapeutics

* SEA's largest independent specialty pharma company Specialised Therapeutics (ST) has joined global pharma consortium committed to collaborating to provide new specialist medicines for rare diseases. * ST to represent WODA in Australia, New Zealand and across Southeast Asia (ANZSEA). * Wor...

2023-09-08 04:00 1435

SOAP Health and AESOP Technology Unite to Provide Advanced AI Solutions for Clinical Decision-Support and Medical Coding

SOAP Health's conversational AI for medical encounters, risk and symptom assessment, and documentation integrates with AESOP Technology's electronic medical record data analysis for clinical decision optimization, coding, and productivity. BOCA RATON, Fla., Sept. 7, 2023 /PRNewswire/ -- SOAP Hea...

2023-09-07 21:00 1324